(Q31017562)

28 June 2017

1 reference

title

Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials (English)

1 reference

28 June 2017

3

Douglas G Altman

1 reference

28 June 2017

Matthew R Sydes

1

0 references

author name string

David J Spiegelhalter

2

1 reference

28 June 2017

Abdel B Babiker

4

1 reference

28 June 2017

Mahesh K B Parmar

5

1 reference

28 June 2017

DAMOCLES Group

6

1 reference

28 June 2017

publication date

1 February 2004

1 reference

28 June 2017

1 reference

28 June 2017

volume

1

1 reference

28 June 2017

issue

1

1 reference

28 June 2017

page(s)

60-79

1 reference

Early stopping rules--clinical perspectives and ethical considerations.

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Monitoring and ensuring safety during clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Should all trials have a data safety and monitoring committee?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Behind closed doors: the data monitoring board in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Monitoring of clinical trials and interim analyses from a drug sponsor's point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Are safety committees really safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The management of interim analyses in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The agonising negative trend in monitoring of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Some FDA perspectives on data monitoring in clinical trials in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The NHLBI model: a 25 year history

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Monitoring of clinical trials: issues and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Some practical aspects of the interim monitoring of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. Roles and membership of data monitoring committees for trials sponsored by the National Eye Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Interim analyses, stopping rules and data monitoring in clinical trials in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring committees and interim monitoring guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring committees and capturing relevant information of high quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Monitoring and evaluating clinical trials data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Procedures of data and safety monitoring committees

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

On being the statistician on a Data and Safety Monitoring Board

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

A survey of monitoring practices in cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Interim analysis in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The case against independent monitoring committees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring committees: the moral case for maximum feasible independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring committees for Southwest Oncology Group clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Monitoring clinical trials--interim data should be publicly available

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Statistical and ethical issues in monitoring clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The role of external evidence in data monitoring of a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Role of external evidence in monitoring clinical trials: experience from a perinatal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Should data and safety monitoring boards share confidential interim data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring committees and problems of lower-than-expected accrual or events rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data monitoring boards in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Stopping guidelines for clinical trials with multiple treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

When to stop a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Clinical trial safety committees: the devil's spoon

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Stopping the active intervention: CARET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Termination of a randomized controlled trial of two vasectomy techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The relationship between clinical trials and clinical practice: the risks of underestimating its complexity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

The Data and Safety Monitoring Committee: Some final thoughts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Statistical approaches and policies for the operations of Data and Safety Monitoring Committees

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Should local research ethics committees monitor research they have approved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Trials stopped early: too good to be true?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Secrecy for data monitoring committees: inferior ethics, bad policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Changes in clinical trials mandated by the advent of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Data-monitoring committees in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

How should results from completed studies influence ongoing clinical trials? The CAFA Study experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Policies for study monitoring and interim reporting of results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Practical aspects in data monitoring: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1740774504CN004RR

10.1191/1740774504CN004RR

21 January 2018

Identifiers

DOI

1 reference

28 June 2017

1 reference